Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk is doing exceptionally well in the ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it is not inferior to Norditropin, Sogroya is ...

Novo Nordisk has started building ... up 3% on the same period of 2023 - but Novo Nordisk has a stated ambition of generating a "sustained growth outlook" for the business as sales of some ...

Novo Nordisk's 2024 earnings exceeded estimates ... a once-weekly treatment for growth hormone deficiency. As for blood disorders, sales also grew by 3%, boosted by increased sales of products ...

Novo Nordisk forecast slower sales growth for 2025 of between 16% to 24 ... work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

The company's GLP-1 receptor agonist products, Ozempic (semaglutide) for type 2 diabetes and Wegovy (semaglutide) for weight management, have been driving significant growth and market share gains. In ...